文献速递关节外科

单名高手术量关节置换外科医生20年间假体周围关节感染微生物趋势与再感染复发情况

Trends of Prosthetic Joint Infection Organisms and Recurrence for a Single High-Volume Arthroplasty Surgeon Over 20 Years.
PubMed 文献 · J Arthroplasty · 2020-10-13

回顾性分析1995至2018年单名高手术量翻修关节置换外科医生治疗的261例假体周围关节感染(PJI)患者,1年和5年再感染率分别为15.8%和22.1%,微生物种类及抗生素耐药性随时间无显著变化;肌肉骨骼感染病(MSK ID)专科会诊总体未降低再感染风险,但在既往有PJI的患者中再感染风险似乎略低。

要点

  • 261例PJI患者1年再感染率15.8%(95%CI 11.6-20.7),5年再感染率22.1%(95%CI 17.0-27.7)。
  • 微生物种类和抗生素耐药性在20年间无显著变化。
  • MSK ID会诊患者再感染风险与无会诊者相似(HR 1.02,95%CI 0.6-1.75,P=0.93)。

核心结论

  • 单中心20年间PJI微生物和抗生素耐药性差异极小,提示当前PJI治疗标准在多数病例中仍然有效。
  • MSK ID参与总体上与再感染风险降低无关。
  • 在既往有PJI的患者中,MSK ID参与时再感染风险似乎略低。

研究设计与样本

  • 回顾性评估1995年至2018年间由单名高手术量翻修关节置换外科医生连续治疗的所有全关节置换(TJA)后PJI患者,共261例,中位年龄66岁(四分位距57-75)。
  • 调查微生物身份、抗生素耐药、既往PJI及MSK ID会诊情况。
  • 证据等级为IV级-病例系列。

主要发现

  • 1年再感染率为15.8%(95%CI 11.6-20.7),5年再感染率为22.1%(95%CI 17.0-27.7)。
  • 微生物身份和抗生素耐药性随时间无显著变化。
  • MSK ID管理组中既往PJI患者更多(53.3% vs 37.6%,P=0.012),但再感染率与非MSK ID管理组相似(HR 1.02,95%CI 0.6-1.75,P=0.93)。
  • 既往PJI与更高的再感染风险相关(HR 2.39,95%CI 1.39-4.12,P=0.002);在无MSK ID会诊患者中该风险为HR 2.78(95%CI 1.37-5.65,P=0.005);在有MSK ID会诊的既往PJI患者中该风险略低且未达统计学显著(HR 1.97,95%CI 0.87-4.48,P=0.106)。

关键数值与推荐

  • 原文未报告具体诊断标准或推荐条款。

临床怎么用

  • 作者指出单中心20年间微生物和抗生素耐药性差异极小,提示当前PJI治疗标准在多数病例中仍然有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prosthetic joint infection (PJI) is a morbid complication following total joint arthroplasty (TJA). PJI diagnosis and treatment has changed over time, and patient co-management with a high-volume musculoskeletal infectious disease (MSK ID) specialist has been implemented at our institution in the last decade. METHODS: We retrospectively evaluated all consecutive TJA patients treated for PJI between 1995 and 2018 by a single high-volume revision TJA surgeon. Microbial identities, antibiotic resistance, prior PJI, and MSK ID consultation were investigated. RESULTS: In total, 261 PJI patients (median age 66 years, interquartile range 57-75) were treated. One-year and 5-year reinfection rates were 15.8% (95% confidence interval [CI] 11.6-20.7) and 22.1% (95% CI 17.0-27.7), respectively. Microbial identities and antibiotic resistances did not change significantly over time. Despite seeing more prior PJI patients (53.3% vs 37.6%, P = .012), MSK ID-managed patients had similar infection rates as non-MSK ID-managed patients (hazard ratio [HR] 1.02, 95% CI 0.6-1.75, P = .93). Prior PJI was associated with higher reinfection risk (HR 2.39, 95% CI 1.39-4.12, P = .002) overall and in patients without MSK ID consultation, specifically (HR 2.78, 95% CI 1.37-5.65, P = .005). This risk was somewhat lower and did not reach significance in prior PJI patients with MSK ID consultation (HR 1.97, 95% CI 0.87-4.48, P = .106). CONCLUSION: We noted minimal differences in microbial/antibiotic resistances for PJI over 20 years in a single institution, suggesting current standards of PJI treatment remain encouragingly valid in most cases. MSK ID involvement was not associated with lower reinfection risk overall; however, in patients with prior PJI, the risk of reinfection appeared to be somewhat lower with MSK ID involvement. LEVEL OF EVIDENCE: Level IV-Case Series.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Yeung CM, Suhardi VJ, Varady NH, et al. Trends of Prosthetic Joint Infection Organisms and Recurrence for a Single High-Volume Arthroplasty Surgeon Over 20 Years. J Arthroplasty. 2020. PMID: 33160807. doi:10.1016/j.arth.2020.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。